Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •One of the following histologically or cytologically confirmed diseases:
• •* Indolent B-cell non-Hodgkin's lymphoma (NHL)
• •* Stage II-IV disease
• •* Chronic lymphocytic leukemia (CLL) meeting 1 of the following risk criteria:
• •* Intermediate-risk with progressive disease
• •* High-risk, modified Rai stage disease
• •CD20-positive by flow cytometry or immunohistochemistry
• •Measurable disease
• •Rituximab-refractory disease, defined as failure to achieve a response to the last course of prior treatment with rituximab alone or in combination with other therapeutic modalities
• •No known neoplastic leptomeningeal involvement and/or brain metastases
• •PATIENT CHARACTERISTICS:
• •Age
• •18 and over
• •Performance status
• •ECOG 0-2 OR
• •Karnofsky 60-100%
• •Life expectancy
• •More than 3 months
• •Hematopoietic
• •Absolute neutrophil count ≥ 1,500/mm\^3
• •Platelet count ≥ 50,000/mm\^3
• •WBC ≥ 3,000/mm\^3
• •Hepatic
• •AST and ALT ≤ 2.5 times upper limit of normal
• •Bilirubin normal (unless due to Gilbert's disease or organ involvement by NHL or CLL)
• •Renal
• •Creatinine normal OR
• •Creatinine clearance ≥ 60 mL/min
• •Cardiovascular
• •No symptomatic congestive heart failure
• •No unstable angina pectoris
• •No cardiac arrhythmia
• •Other
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •HIV negative
• •No history of anaphylaxis or immunoglobulin (Ig) E-mediated hypersensitivity to murine protein
• •* Prior infusion reactions to rituximab without an IgE component allowed
• •No active or ongoing infection
• •No psychiatric illness or social situation that would preclude study compliance
• •No other uncontrolled illness
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •See Disease Characteristics
• •See Radiotherapy
• •At least 12 weeks since prior rituximab
• •More than 4 weeks since prior immunotherapy and recovered
• •Chemotherapy
• •No more than 3 prior chemotherapy regimens
• •More than 4 weeks since prior chemotherapy and recovered
• •Endocrine therapy
• •No concurrent glucocorticoids
• •Radiotherapy
• •At least 12 weeks since prior radioimmunotherapy
• •More than 4 weeks since prior radiotherapy and recovered
• •Surgery
• •Not specified
• •Other
• •At least 4 weeks since prior therapy for the malignancy
• •No other concurrent anticancer therapy
• •No other concurrent investigational agents